Michael J. Gresser
Geen lopende functies
Profiel
Michael J.
Gresser worked as a Director at Trillium Therapeutics, Inc. from 2010 to 2014.
He was a Biochemistry Director at Merck Frosst Canada Ltd.
He also worked as a Vice President-Research at Amgen, Inc. from 2000 to 2006.
He was a Chief Scientific Officer-Elect at Oxford BioTherapeutics Ltd.
He worked as a Principal at the University of California, Los Angeles and as a Professor at Simon Fraser University.
Gresser earned a doctorate degree from Brandeis University in 1976.
Eerdere bekende functies van Michael J. Gresser
| Bedrijven | Functie | Einde |
|---|---|---|
Trillium Therapeutics, Inc. /Old/
 Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Directeur/Bestuurslid | 06-06-2014 |
| AMGEN INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2006 |
Merck Frosst Canada Ltd.
 Merck Frosst Canada Ltd. Pharmaceuticals: MajorHealth Technology Merck Frosst Canada Ltd. is a Canadian pharmaceutical company that has been inventing medicines and vaccines for over 130 years. The company is based in Kirkland, Canada. The company's mission is to save and improve lives by bringing forward solutions for some of the world's most challenging diseases. | Corporate Officer/Principal | - |
| Simon Fraser University | Corporate Officer/Principal | - |
| University of California, Los Angeles | Corporate Officer/Principal | - |
Opleiding van Michael J. Gresser
| Brandeis University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| AMGEN INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Merck Frosst Canada Ltd.
Merck Frosst Canada Ltd. Pharmaceuticals: MajorHealth Technology Merck Frosst Canada Ltd. is a Canadian pharmaceutical company that has been inventing medicines and vaccines for over 130 years. The company is based in Kirkland, Canada. The company's mission is to save and improve lives by bringing forward solutions for some of the world's most challenging diseases. | Health Technology |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Commercial Services |